Key facts
- This page summarizes FMR LLC's Form 4 filing for Bicara Therapeutics Inc. (BCAX).
- 6 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 18 Sep 2024, 11:54.
FMR LLC - 16 Sep 2024 Form 4 Insider Report for Bicara Therapeutics Inc. (BCAX)
- Reporting relationship
- Other*
- Issuer ticker
- BCAX
- Reported as of
- 16 Sep 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 18 Sep 2024, 11:54:10 UTC
- Prior SEC filing
- 12 Sep 2024
- Next SEC filing
- 10 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- Stephanie J. Brown, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
FMR LLC filed Form 4 for Bicara Therapeutics Inc. (BCAX) on 18 Sep 2024.
Change
- Previous filing in this sequence was filed on 12 Sep 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BCAX
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +10,818
- Change %
- Price
- Shares after
- 10,818
- Date
- 16 Sep 2024
- Ownership
- F-Prime Capital Partners Life Sciences Fund VII LP
- Footnotes
- F1
BCAX
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +712,430
- Change %
- +6586%
- Price
- Shares after
- 723,248
- Date
- 16 Sep 2024
- Ownership
- F-Prime Capital Partners Life Sciences Fund VII LP
- Footnotes
- F1
BCAX
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +392,085
- Change %
- +54%
- Price
- Shares after
- 1,115,333
- Date
- 16 Sep 2024
- Ownership
- F-Prime Capital Partners Life Sciences Fund VII LP
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BCAX
transaction
Derivative
Series Seed Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -10,818
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 16 Sep 2024
- Ownership
- F-Prime Capital Partners Life Sciences Fund VII LP
- Underlying class
- Common Stock
- Underlying amount
- 10,818
- Exercise price
- Footnotes
- F1
BCAX
transaction
Derivative
Series B Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -712,430
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 16 Sep 2024
- Ownership
- F-Prime Capital Partners Life Sciences Fund VII LP
- Underlying class
- Common Stock
- Underlying amount
- 712,430
- Exercise price
- Footnotes
- F1
BCAX
transaction
Derivative
Series C Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -392,085
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 16 Sep 2024
- Ownership
- F-Prime Capital Partners Life Sciences Fund VII LP
- Underlying class
- Common Stock
- Underlying amount
- 392,085
- Exercise price
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
FMR LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 1 footnote
Footnote F1
On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.
SEC remarks
Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: F-Prime Capital Partners Life Sciences Advisors Fund VII LP (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VII LP. FPCPLSA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family.